You are here Home page > Implementations > Roche Launches Elecsys Syphilis Immunoassay
Published 20 March 2014

Roche Launches Elecsys Syphilis Immunoassay

7 Votes

Basel-based Roche announced that it has launched Elecsys Syphilis immunoassay to help detect patients infected with syphilis and help in the prevention of donating syphilis-infected blood.

Syphilis is a sexually transmitted infection induced by the bacterium Treponema pallidum subspecies pallidum. Around 36 million people are infected with syphilis around the world, with 12 million new cases reported every year. Syphilis is primarily transmitted through sexual contact, but can also be passed on through blood transfusions and between mothers and their unborn child.

The new diagnostic test is designed to be highly sensitive in detecting infected blood. Healthcare professionals in laboratory settings will be able to run a single test in less than 20 minutes, ensuring safe and timely supply of blood products. Roche said the diagnostic test has minimal requirements for re-tests and maximizes efficiency gains for both laboratory and patient safety.
Elecsys is designed to complement the most comprehensive options for blood safety on the market.

On the web: